-+ 0.00%
-+ 0.00%
-+ 0.00%

ANI Pharmaceuticals to present Phase 4 SYNCHRONICITY trial data on fluocinolone acetonide intravitreal implant at AAO 2026 meeting

PUBT·09/30/2026 10:55:25
Listen to the news
ANI Pharmaceuticals to present Phase 4 SYNCHRONICITY trial data on fluocinolone acetonide intravitreal implant at AAO 2026 meeting
  • ANI Pharmaceuticals announced upcoming presentations of Phase 4 data for its fluocinolone acetonide intravitreal implant at AAO 2026.
  • SYNCHRONICITY trial results in chronic non-infectious posterior uveitis will be presented Oct. 9, 2026 in a late-breaking oral session.
  • Management highlighted prior disclosure of six-month topline results in July 2026, with additional findings set for the AAO update.
  • Post-hoc NEW DAY analyses in diabetic macular edema will be released as an on-demand ePoster, comparing outcomes in rescued versus non-rescued patients.
  • Company also scheduled an encore podium presentation of SYNCHRONICITY results at Hawaiian Eye & Retina on Jan. 21, 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ANI Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300655PRIMZONEFULLFEED9836269) on September 30, 2026, and is solely responsible for the information contained therein.